Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

445
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
445
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

2.2K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.2K
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

437
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
437
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

346
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
346
Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

1.1K
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Early STAT3 Activation and Delayed STAT5 Dominance Define the Acute Leukocyte Signaling Response to Trauma and May Correlate with Clinical Outcomes.

Shock (Augusta, Ga.)·2026
Same author

Increased mortality in children with severe trauma and bleeding: Hypotheses and methods to reduce the risk.

Transfusion·2026
Same author

Lyophilized Synthetic Platelets: In Vitro Characterization and in Vivo Evaluation in Mouse Thrombocytopenia Model.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026
Same author

Low titer group O whole blood inventory conservation: The effect of implementing group A whole blood at a simulated civilian trauma center.

Transfusion·2026
Same author

Utilization and safety outcomes following the use of low titer group O whole blood in non-trauma patients.

Transfusion·2026
Same author

Consensus-based criteria for actionable hemorrhage in pediatric trauma: A Delphi study.

The journal of trauma and acute care surgery·2026
Same journal

Critical Care and Contagion: Evolving Frontiers of Infectious Diseases in the Modern Intensive Care Unit.

Critical care clinics·2026
Same journal

Advances and Challenges in Sepsis Care in Low-Resource Settings.

Critical care clinics·2026
Same journal

The Respiratory Triple Pandemic in the Intensive Care Unit: Epidemiology, Clinical Features and Management of COVID-19, Influenza and Respiratory Syncytial Virus.

Critical care clinics·2026
Same journal

Antibiotic Stewardship for the Intensivist.

Critical care clinics·2026
Same journal

Infection Prevention and Control in the Intensive Care Unit.

Critical care clinics·2026
Same journal

Antibiotic Considerations in the Critically Ill: Empiric Choices and Dosing.

Critical care clinics·2026
See all related articles

Related Experiment Video

Updated: Mar 11, 2026

A New Hybrid Quantitative Evaluation Model for Axillary Junctional Hemorrhage in Swine
08:27

A New Hybrid Quantitative Evaluation Model for Axillary Junctional Hemorrhage in Swine

Published on: December 6, 2024

714

Tranexamic Acid Update in Trauma.

Ricardo J Ramirez1, Philip C Spinella2, Grant V Bochicchio1

  • 1Department of Surgery, Washington University School of Medicine, 660 South Euclid Avenue, St Louis, MO 63110, USA.

Critical Care Clinics
|November 30, 2016
PubMed
Summary
This summary is machine-generated.

Tranexamic acid (TXA) shows promise in reducing trauma patient mortality within 3 hours of injury. Further research is needed to optimize its use, including dosing, timing, and patient selection through methods like viscoelastic testing.

Keywords:
AntifibrinolyticsCoagulopathyHemorrhageSurgeryTranexamic acidTrauma

More Related Videos

Complete and Partial Aortic Occlusion for the Treatment of Hemorrhagic Shock in Swine
09:37

Complete and Partial Aortic Occlusion for the Treatment of Hemorrhagic Shock in Swine

Published on: August 24, 2018

11.0K
Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.8K

Related Experiment Videos

Last Updated: Mar 11, 2026

A New Hybrid Quantitative Evaluation Model for Axillary Junctional Hemorrhage in Swine
08:27

A New Hybrid Quantitative Evaluation Model for Axillary Junctional Hemorrhage in Swine

Published on: December 6, 2024

714
Complete and Partial Aortic Occlusion for the Treatment of Hemorrhagic Shock in Swine
09:37

Complete and Partial Aortic Occlusion for the Treatment of Hemorrhagic Shock in Swine

Published on: August 24, 2018

11.0K
Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.8K

Area of Science:

  • Trauma care
  • Hemorrhage management
  • Pharmacology

Background:

  • The CRASH-2 trial highlighted tranexamic acid (TXA) for trauma-related hemorrhage.
  • TXA demonstrates efficacy in reducing mortality when administered within 3 hours of injury.
  • Optimal use of TXA requires further investigation into dosing, timing, and pharmacokinetics.

Purpose of the Study:

  • To explore the optimal use of tranexamic acid in trauma patients.
  • To investigate the role of fibrinolysis shutdown and viscoelastic testing in patient selection for TXA therapy.
  • To inform the integration of TXA into trauma networks.

Main Methods:

  • Review of existing clinical trial data, including CRASH-2.
  • Discussion of fibrinolysis shutdown concepts in hemorrhagic trauma.
  • Consideration of real-time viscoelastic testing for patient selection.

Main Results:

  • TXA is effective in reducing mortality in trauma patients presenting within 3 hours of injury.
  • Further research is required to fully understand TXA's optimal dosing, timing, and pharmacokinetic profile.
  • Real-time viscoelastic testing is being explored for improved patient selection.

Conclusions:

  • Tranexamic acid is a valuable tool in managing trauma-related hemorrhage.
  • Ongoing clinical trials are crucial for establishing evidence-based guidelines for TXA use.
  • Optimizing TXA administration and patient selection will enhance its impact on trauma care outcomes.